Epcoritamab in Previously Treated WM

NCT06510491 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Waldenstrom Macroglobulinemia
B-Cell Lymphoproliferative Disorder

Interventions

DRUG: Epcoritamab

Sponsor

Gottfried von Keudell, MD PhD

Collaborators

[object Object]